4James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera [ J ]. Nature,2005,434 : 1144 - 1148.
5Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disordcrs[J]. N Engl J Med, 2005,352 : 1779 - 1790.
6Hsu HC, Wu HS, Hon YC, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in Taiwan Residents patients with myeloproliferative disorders [ J ]. Haematologica, 2006,91 ( Suppl ) :457.
7Suning Chen, Hairong Fei, Ri Zhang, et al. Analysis of JAK2 V617F Mutation in Chinese Patients With Myeloproliferative Disorders [ J ]. American Journal of Hematology,2007,82:458 - 459.
8Thomas Stauffer Larsen, Jacob Haaber Christensen, Hans Carl Hasselbalchl ,et al. The JAK2 V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders [ J ]. British Journal of Haematology,2007,136:745 - 751.
9Kohtaro Toyama, Masarnitsu Karasawa, Arito Yamane. JAK2-Vr17F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets [ J ]. British Journal of Haematology ,2007 ,139 :64 - 69.
10Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617Fmutation of JAK2 [ J ]. Blood, 2005, 106:3374 - 3376.
